US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

3.180 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Esperion Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger ↗
Stockholders of Esperion Therapeutics (NASDAQ:ESPR) approved the company’s merger agreement with Essence Parent and Essence MergerCo at a special meeting held virtually on July 8, 2026, according to... 
Via MarketBeat
News headline image
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Friday's session: most active stocks ↗
Via Chartmill
Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q4 2025 Results Amid Strategic Expansion ↗
Via Chartmill
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether SILA, ESPR, CRBG, EQH are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether SILA, LSTA, ESPR are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq -
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
From Kahn Swick & Foti, LLC
Via Business Wire
What's going on in today's session ↗
Via Chartmill
News headline image
Veeva Systems, Five9, AXT And Other Big Stocks Moving Higher On Friday ↗
US stocks were mixed on Friday, with Dow Jones down 0.1%. Veeva Systems Inc (NYSE: VEEV) rose 11.6%, joining S&P 500 on May 7. Other big gainers: Esperion Therapeutics Inc (NASDAQ: ESPR), Five9 Inc... 
Via Benzinga
Topics Artificial Intelligence Stocks
Which stocks are moving on Friday? ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Esperion to be Acquired by ARCHIMED
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Report First Quarter 2026 Financial Results on May 7
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
From Athyrium Capital Management, LP
Via GlobeNewswire
News headline image
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts ↗
Esperion reported earnings per share of $0.22 on revenue of $168.5 million, while Wall Street expected an EPS of $0.28 on revenue of $164.7 million. 
Via Stocktwits
Topics Intellectual Property
News headline image
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
From Corstasis Therapeutics Inc.
Via Business Wire
News headline image
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >